R&D Archives - Pharmaphorum

Ablynx and Sanofi sign potential 2.4bn euro R&D deal

July 20, 2017

Collaboration will develop drugs for inflammatory diseases

Ablynx and Sanofi sign potential 2.4bn euro R&D deal

https://pharmaphorum.com/news/ablynx-sanofi-sign-potential-2-4-bn-euros-rd-deal/

Promise of CF combinations lifts Vertex, reignites takeover interest

July 19, 2017

Encouraging results from three pipeline combination therapies suggests Vertex could extend treatment to patients with more severe and difficult to treat

Promise of CF combinations lifts Vertex, reignites takeover interest

https://pharmaphorum.com/news/vertex-hopes-pipeline-combos-will-expand-cf-offering/

Surge of Alzheimer’s drugs in pipeline gives hope of progress

July 18, 2017

Authors “optimistic” despite issues with front runners from AB Science and Otsuka

Surge of Alzheimer’s drugs in pipeline gives hope of progress

https://pharmaphorum.com/news/35-alzheimers-drugs-hit-market-2022-report/

AstraZeneca CEO Soriot may stay after all

July 17, 2017

Soriot to host results announcement as usual

AstraZeneca CEO Soriot may stay after all

https://pharmaphorum.com/news/astrazeneca-ceo-soriot-may-stay/

Novartis CAR-T safety in FDA spotlight

July 11, 2017

FDA advisers are set to make recommendations on Novartis’ groundbreaking CAR-T therapy CTL019 tomorrow – and are set to

Novartis CAR-T safety in FDA spotlight

https://pharmaphorum.com/news/fda-advisers-consider-novartis-car-t-safety/

2nd Annual Cancer Immunotherapy Summit

July 10, 2017

Advanced methods in Cancer Immunotherapy

2nd Annual Cancer Immunotherapy Summit

https://pharmaphorum.com/events/2nd-annual-cancer-immunotherapy-summit/

EMA and FDA aim to slash Gaucher disease R&D costs

July 5, 2017

Proposals include multi-company trial.

EMA and FDA aim to slash Gaucher disease R&D costs

https://pharmaphorum.com/news/ema-fda-encourage-gaucher-rd/

Alder shares slump despite migraine success

June 28, 2017

Investors concerned over strong placebo effect

Alder shares slump despite migraine success

https://pharmaphorum.com/news/alder-shares-slump-despite-migraine-success/

Merck & Co hit by GoldenEye ransomware

June 28, 2017

Attack overshadows surprise success for cholesterol drug

Merck & Co hit by GoldenEye ransomware

https://pharmaphorum.com/news/merck-co-hit-goldeneye-virus/

Trending

R&D

Ablynx and Sanofi sign potential 2.4bn euro R&D deal

Promise of CF combinations lifts Vertex, reignites takeover interest

Surge of Alzheimer’s drugs in pipeline gives hope of progress

AstraZeneca CEO Soriot may stay after all

Novartis CAR-T safety in FDA spotlight

2nd Annual Cancer Immunotherapy Summit

EMA and FDA aim to slash Gaucher disease R&D costs

Alder shares slump despite migraine success

Merck & Co hit by GoldenEye ransomware

Inhalation and Respiratory Drug Products Summit

THET Annual Conference 2017

Clinical Trial Supply East Coast 2017

Livongo’s diabetes solution impresses in latest study

Vifor’s hyperkalaemia drug Veltassa approved in Europe

New 3-year data supports Kite ‘cure’ hopes for CAR-T

Daiichi Sankyo anticoagulant gains EU label boost

Teva’s Cinqaero to challenge Nucala after clearing NICE

The most notable digital health trends of 2017 so far

Europe has untapped medical innovation – but needs high speed connections to make it work

Healthcare’s hype cycle: which technologies will stay the course?

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

What HCPs say about Roche’s breast cancer drug

Search

Advanced Search

Trending

R&D